Centre for Global Child Health at The Hospital for Sick Children (SickKids) - Global Child Health (CGH) Fellowship - Stanford University

For years, Doan Quang Dung, an applied epidemiologist at the Queensland Health Department in Australia, worked within the limits of his laboratory bench: specimens, reagents, a microscope. Then COVID-19 shifted his world, and the period of forced reflection drove him “to look beyond the lab, and at populations that were most at risk of disease.” What began as curiosity during a crisis became a mission, and it led him to the World Health Organization’s Field Epidemiology Fellowship Programme (FEFP) in the Western Pacific.  “FEFP provided an eye-opening transition from the controlled lab to the ‘boots on the ground’ reality of field epidemiology, where I worked with complex datasets to uncover the causes and effects of disease,” he shared. This year, that programme turns 20. From mentorship to a regional engine FEFP was established in 2006, to help countries detect and respond rapidly to emerging infections and other acute public health events. Initially individual and mentorship-based, in 2011 it became more structured.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.